sofosbuvir/velpatasvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   29 Trials   29 Trials   1253 News 


«12345678910111213...1920»
  • ||||||||||  Successfully Treated Acute Liver Injury in Acute Hepatitis C With N- Acetyl Cysteine: A Case Report (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_4043;    
    He was given 140 mg/kg oral N-acetylcysteine for suspected acetaminophen overdose as the etiology for liver injury...The patient was prescribed Sofosbuvir-Velpatasvir at discharge for the treatment of acute hepatitis C. In patients with hepatitis C infection the rate of liver injury with acute or chronic infection is about 16.7%...This case also highlights further studies are needed to determine the incidence and implications of acute liver injury in acute hepatitis C patients as there are no studies in this group of patients so far. Table: Liver Function Tests During Admission
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., methylprednisolone sodium succinate / Generic mfg., ursodeoxycholic acid / Generic mfg.
    Fibrosing Cholestatic Hepatitis Masquerading Acute Cellular Rejection in HCV-Positive Donor Liver Graft (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_1687;    
    Considering the donor was HCV+, Hepatitis C RNA, PCR was done on 3/1/22 which was >100000000 IU/mL, at this point patient was started on EPCLUSA (sofosbuvir-velpatasvir)...B: Arrow pointing towards pigment deposition showing intrahepatic cholestasis. Table: Table-1: Trend in LFTs and HCV RNA viral load over hospital course following deceased donor HCV+ OLT
  • ||||||||||  dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan
    Acute Hepatitis C Infection Accounts for Suspected Isoniazid Hepatitis in a Patient With Controlled HIV Infection on Antiretroviral Therapy (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_811;    
    He has a history of controlled HIV infection on dolutegravir/tenofovir/emtricitabine, non-monogamy (men having sex with men), marijuana/herbal use, and latent tuberculosis (with a normal liver test/negative HCV antibody) treated with INH for 3 months...Sofosbuvir-velpatasvir treatment was initiated with rapid normalization of ALT/AST and decreasing HCV RNA...The case emphasizes the importance of early HCV RNA testing for diagnosing/excluding acute HCV infection in suspicious DILI due to delayed seroconversion of HCV antibody. Prompt treatment with highly potent antiviral agents leads to eradication of HCV with potential public health benefit.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    A Case of Immediate Hepatitis C Infection Leading to Cholestatic Hepatitis With Significant Viremia After Liver Transplantation (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_533;    
    The patient was started on Sofosbuvir / Velpatasvir for the treatment of HCV on POD 9...Since the genotype of HCV from the donor is not routinely evaluated, it is recommended to use a pan-genotypic regimen (Glecaprevir/Pibrentasvir or Sofosbuvir/Velpatasvi)...d. Trichrome stain shows no delicate periportal strands of "chicken wire" like pericellular fibrosis; an early fibrosing cholestatic hepatitis is still under consideration.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    New trial:  Eliminating HCV Infection Among PWUD (clinicaltrials.gov) -  Jul 26, 2022   
    P=N/A,  N=300, Recruiting, 
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study. (Pubmed Central) -  Jul 17, 2022   
    In conclusion, this case series study found that sofosbuvir-based therapy for pregnant women and infant with severe CHC is safe and effective. The data may fill the gap and provide evidence of the use of sofosbuvir-based therapy as a reference when similar severe CHC situations are encountered during clinical practice.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Journal:  Rapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized Trial. (Pubmed Central) -  Jul 14, 2022   
    Participants randomized to Rapid Treatment received same-day medical evaluation, confirmatory and baseline laboratory testing, and a 7-day starter pack of sofosbuvir/velpatasvir at a syringe service program (SSP)...Among young HCV RNA PWID, significantly higher rates of cure were achieved using the Rapid Treatment model compared with facilitated referral. Providing easy access to HCV treatment for young PWID in low-threshold settings and initiating HCV treatment quickly appears to be a promising strategy for treating this hard-to-reach population.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Vemlidy (tenofovir alafenamide) / Gilead
    Retrospective data, Journal:  Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. (Pubmed Central) -  Jun 22, 2022   
    SOF-based regimens had 2.72-fold higher relative risk (RR) causing 10% elevation of TC (95% CI 1.84-4.02, p < 0.001) and 2.04-fold higher RR causing 10% elevation of LDL-C (95% CI 1.39-3.01, p < 0.001) than non-SOF-based DAAs. SOF-based DAAs were associated with significantly larger amplitude of increases in TC and LDL-C than non-SOF-based DAAs during the initial 4 weeks of treatment, but the increases were not sustained to SVR12.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment closed, Enrollment change:  The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study (clinicaltrials.gov) -  Jun 8, 2022   
    P4,  N=86, Active, not recruiting, 
    A liver transplant patient exhibited viral clearance of hepatitis C following administration of crushed sofosbuvir/velpatasvir in the setting of multiple absorption concerns. Enrolling by invitation --> Active, not recruiting | N=150 --> 86
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date:  Lung Transplant HCV, Pilot Study (clinicaltrials.gov) -  May 25, 2022   
    P1,  N=26, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting | N=150 --> 86 Trial completion date: Apr 2022 --> Apr 2023
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Outcomes in Hepatitis C (HCV) Viremic Grafts to HCV Negative Recipients in Heart Transplantation: A Multicenter Study of Differing Treatment Strategies (Hynes Halls C & D: Board No. D147) -  May 20, 2022 - Abstract #ATC2022ATC_2936;    
    4 patients were treated preemptively per a study protocol with glecaprevir/pibrentasvir (G/P) and ezetimibe, 1 dose prior to surgery followed by 7 days of therapy...All viremic patients were treated reactively with sofosbuvir/velpatasvir (S/V) for 12 weeks (6 patients), G/P for 8 weeks (1 patient), or G/P for 12 weeks (4 patients) per insurance preference... Despite various treatment regimens and strategies, all patients were cured of hepatitis C, had reduced time on the waiting list and had similar post-transplant cardiac function.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD)
    The SHELTER Trial of Transplanting Donor Hepatitis C Virus RNA+ Lungs Into Uninfected Recipients (Hynes Room 210) -  May 20, 2022 - Abstract #ATC2022ATC_2043;    
    P1/2
    HCV-negative candidates who underwent lung transplant with HCV-RNA+ donor organs responded well to antiviral therapy and had acceptable 1-year outcomes. The SHELTER trial also revealed new and reassuring data about quality of life after transplant using HCV-RNA+ lungs.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Review, Journal:  Chronic hepatitis C: Diagnosis and treatment made easy. (Pubmed Central) -  May 18, 2022   
    However, patients with comorbidities, cirrhosis or coinfection (HIV, Hepatitis B Virus (HBV)) should be referred to the liver clinic. In case of screening patients with risk factors or likelihood of dormant HCV, health organisations should provide the appropriate resources, logistics, finances and workforce.
  • ||||||||||  Cost versus price of key drugs to treat COVID-19, HIV, HBV and HCV () -  May 12, 2022 - Abstract #AIDS2022AIDS_2061;    
    In case of screening patients with risk factors or likelihood of dormant HCV, health organisations should provide the appropriate resources, logistics, finances and workforce. Key viral infections can be treated or cured with generic drugs at prices far below those of branded equivalents.Use of branded drugs at high prices can limit the potential for countries to achieve the UNAIDS 95-95-95 targets.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021 (Poster Area) -  May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2232;    
    With the limitations of FAERS data (under or duplicate reporting, inability to establish causation or incidence), these data showthat among ∼58, 000 fentanyl, ∼189, 000 oxycodone, and ∼100, 000 hydrocodone AEs reported to FAERS since 2017, a small proportion (0.19%) have been reported in association with concomitant DAA therapy, with no association between recorded events and a specific DAA regimen. This should reassure HCV treaters on a lack of safety signal for concomitant opioid and DAA use.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years (Poster Area) -  May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1951;    
    A previously developed lifetime Markov modelwas adapted to estimate HCV morbidity and mortality comparing two treatment alternatives: SOF/VEL versus previous therapies (peginterferon and ribavirin in double/triple therapy with telaprevir or boceprevir). SOF/VEL significantly decreases HCV morbidity and mortality adding value to the management of patients with chronic hepatitis C reducing the clinical and economic burden of the disease and contributing to the goal of disease elimination in Spain.